We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
ImmunityBio Inc

ImmunityBio Inc (IBRX)

( -0.53% )
Updated: 14:15:15

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
5.61 Day's Range 5.81
1.25 52 Week Range 10.53
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
$ 4,643,158
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About ImmunityBio Inc

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Show more

Biological Pds,ex Diagnstics
Biological Pds,ex Diagnstics
Wilmington, Delaware, USA
ImmunityBio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IBRX. The last closing price for ImmunityBio was $5.71. Over the last year, ImmunityBio shares have traded in a share price range of $ 1.25 to $ 10.53.

ImmunityBio currently has 691,567,961 shares outstanding. The market capitalization of ImmunityBio is $3.95 billion. ImmunityBio has a price to earnings ratio (PE ratio) of -38.53.

ImmunityBio (IBRX) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


IBRX Latest News

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP


View all
  • Most Active
  • % Gainers
  • % Losers
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
RGCRegencell Bioscience Holdings Ltd
$ 18.88
SLRXSalarius Pharmaceuticals Inc
$ 3.09
CJETChijet Motor Company Inc
$ 6.11
ATPCAgape ATP Corporation
$ 0.2426
FLYEFly E Group Inc
$ 1.29
RNAZTransCode Therapeutics Inc
$ 0.30
JAGXJaguar Health Inc
$ 1.77
MIRAMIRA Pharmaceuticals Inc
$ 2.5701
IVPInspire Veterinary Partners Inc
$ 6.3676
SPWRSunPower Corporation
$ 1.085
ADILAdial Pharmaceuticals Inc
$ 1.425
SLNASelina Hospitality PLC
$ 0.0257
NVDANVIDIA Corporation
$ 122.765
ATPCAgape ATP Corporation
$ 0.2426

IBRX Discussion

View Posts
Monksdream Monksdream 3 weeks ago
IBRX under $10
jgrabar jgrabar 4 weeks ago
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
tw0122 tw0122 1 month ago
09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 month ago
Any thoughts on how much revenue FDA approval will bring?
wrk_SATX wrk_SATX 2 months ago
Still +54M shares short and time is ticking. 80% inside ownership with a small float.
saigai saigai 2 months ago
up and down.. no problem.. ima staying put
saigai saigai 2 months ago
we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike
carldfw carldfw 3 months ago
Pancreatic Cancer next!!
I like Oncolytics on that list
Tahoe2468 Tahoe2468 3 months ago
7. ImmunityBio Inc (NASDAQ:IBRX)
Float Shorted: 40.37%

With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.
jondoeuk jondoeuk 3 months ago
From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.''

What happened?
jondoeuk jondoeuk 3 months ago
Nothing listed in the pipeline.
Tahoe2468 Tahoe2468 3 months ago
Pancreatic Cancer next!! WOW!!
TrendTrade2016 TrendTrade2016 3 months ago
IBRX monster bio on the weekly break out
MiamiGent MiamiGent 3 months ago
IBRX Friday Close $7.35+$2.24 (+43.84%)

This morning Pre-Mkt
Bid x Size
$8.13 x 2
Ask x Size
$8.20 x 212
90 Day Avg. Vol.

Bona fide squeeze underway. Millions of shares short are trapped.
👍️ 1
carldfw carldfw 3 months ago
Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
pancreatic cancer
. The company's combination immunotherapy
, Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.
martind18 martind18 3 months ago
That’s because IHUB is for pump and dumps.
👍️ 2
Atom Smasher Atom Smasher 3 months ago
Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40
👍️ 2
Monksdream Monksdream 3 months ago
This a simple bar/volume with 60-minute intervals

The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
This a link for the sector that is made up 459 tickers

I have a free membership so I can use the flipcharts function for the past six months of price discovery
One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
The best time to sell was at the peak last March which isn’t that long ago
I can observe the same recurring pattern in the more than 200 tickers I flipped through
Atom Smasher Atom Smasher 3 months ago
Monksdream Monksdream 3 months ago
IBRX in the Barchart Top 10
👍️ 1
axelvento axelvento 3 months ago
Anktiva is the next-generation immunotherapy drug, according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug, as far as I know, that activates the natural killer cell that talks to the T-cell and generates complete remission..."— Yahoo Finance (@YahooFinance) April 23, 2024
👍️ 1
Pt3 Pt3 3 months ago
martind18 martind18 3 months ago
FDA approval!
axelvento axelvento 4 months ago
The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.
Monksdream Monksdream 4 months ago
IBRX chart
Spideyboy Spideyboy 5 months ago
Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

My concern just stems from the bottom of the article stating.

"Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."

There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

Looking to be convinced wrong on the above :)
Monksdream Monksdream 5 months ago
Early Barchart 100
brogers_1 brogers_1 6 months ago
Research tool:
martind18 martind18 7 months ago
mick mick 7 months ago
pilotnick pilotnick 7 months ago
This stock is ready to breakout, did awesome today!!
mick mick 9 months ago
da_stock_analyst da_stock_analyst 9 months ago
#IBRX 🔥 this stock can go crazy with 30% short interest! $IBRX
da_stock_analyst da_stock_analyst 9 months ago
#IBRX 🔥 30% short interest and gap fill possibilities for big move! $IBRX
gail gail 9 months ago
yup, i see that but….


i didnt like how each time it runs, they yank it right back down, so i moved on but im happy it ran for you some. just be careful, they dont seem to last long.
Jess070283 Jess070283 9 months ago
Just warming up…
crudeoil24 crudeoil24 9 months ago
News > Up 29%today > The FDA accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.
gail gail 9 months ago
then the usual dump, lol.
gail gail 9 months ago
nice move so far today
BoilerRoom BoilerRoom 9 months ago
$IBRX looks interesting
gail gail 9 months ago
hopped in on this dip. i like the run it had last time.
Monksdream Monksdream 10 months ago
IBRX under $2
mick mick 10 months ago
mick mick 11 months ago
mick mick 1 year ago
ImmunityBio Inc
0.09 (3.42%)
Volume: 1,135,051
Day Range: 2.60 - 2.75
Last Trade Time: 7:59:29 PM EDT
mick mick 1 year ago
ImmunityBio Inc
-0.12 (-4.27%)
Volume: 6,333,343
Day Range: 2.63 - 2.85
Last Trade Time: 7:51:23 PM EDT
mick mick 1 year ago
ImmunityBio Inc
0.19 (7.98%)
Volume: 2,354,869
Day Range: 2.35 - 2.57
Last Trade Time: 7:56:03 PM EDT
IBRX an offering done right. bonzzzaaaa
da_stock_analyst da_stock_analyst 1 year ago
#IBRX ?? gap fill after 3.3? Trade opportunity? $IBRX
TheFinalCD TheFinalCD 1 year ago
-55% $IBRX received FDA CRL

Recall position was a catalyst play and not an investment which I clearly outlined in my thread.

Multiple times I tweeted that I closed my full position as stock appreciated a lot from entry point (Below $2) to almost 6+

Risk management is important for…— Pharmdca (@Pharmdca) May 11, 2023

Your Recent History

Delayed Upgrade Clock